Related Experiment Video

Updated: May 19, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Role of thrombomodulin gene in Indian population with coronary artery disease

Swarup A Shah1, Tester F Ashavaid, Ranjit Mankeshwar

  • 1Research Laboratories, P. D. Hinduja National Hospital & Medical Research Centre, Mumbai, India.

Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|August 14, 2012
PubMed

Insights

Thrombomodulin (TM) genetic variants did not significantly increase coronary artery disease (CAD) risk. However, the TM Ala455Val substitution was linked to higher CAD risk in Indian subjects aged 49 years and younger.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Medicine
  • Biomarker Discovery

Background:

  • Thrombomodulin (TM) is a natural anticoagulant.
  • TM is implicated in the pathogenesis of coronary artery disease (CAD).
  • TM's role as a potential CAD biomarker is emphasized.

Purpose of the Study:

  • Investigate the role of TM genetic variants in CAD.
  • Assess soluble TM (sTM) plasma levels in the Indian population with CAD.
  • Determine the association between TM genetic variants and CAD risk.

Main Methods:

  • Case-control study design.
  • Genotyping of the entire TM gene.
  • Estimation of sTM plasma levels in 266 subjects.

Main Results:

  • No significant association between four identified TM genetic variants and overall CAD risk.
  • Subgroup analysis revealed a significant association between the C1418T variant (Ala455Val substitution) and CAD in subjects ≤49 years.
  • Soluble TM (sTM) plasma levels were not detailed in the provided abstract summary.

Conclusions:

  • TM Ala455Val substitution is associated with increased CAD risk in younger Indian individuals (≤49 years).
  • This finding suggests a potential role for TM genetic variants in early-onset CAD.
  • Further validation in larger Indian cohorts is necessary to establish clinical utility for screening asymptomatic young subjects.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...